logo-loader
viewShield Therapeutics PLC

Shield Therapeutics supported in negotiations with prospective US partners by new findings, says Peel Hunt

Analysts say completing the negotiations represents significant further upside potential for the company

Shield Therapeutics PLC - Shield Therapeutics' new findings support negotiations with prospective US partners, says Peel Hunt

Shield Therapeutics PLC’s (LON:STX) new findings on its Feraccru /Accrufer will be beneficial to sign up of a partner for the US market, according to house broker Peel Hunt.

Analysts say completing the negotiations represents significant further upside potential for the company, which is focussed on addressing iron deficiency.

READ: Shield Therapeutics soars as reanalysis of Feraccru study finds positive results

According to Peel Hunt, the reviewed data are also supportive of the existing EU and Chinese commercial partners’ marketing efforts.

Late on Thursday, the specialty pharmaceutical firm released findings of a reanalysis of the AEGIS-H2H study, indicating that Feraccru/Accrufer is a credible alternative to IV therapy for iron deficiency anaemia and corrects anaemia and maintains iron levels over the long term.

“Feraccru’s comparable improvement in haemoglobin in the long-term data against IV, combined with its greater tolerability, significantly more convenient oral administration, and compelling economic benefits, constitutes a very strong marketing package for EU commercialisation partner Norgine to leverage into the market,” analysts commented.

Peel Hunt pointed out that many intravenous (IV) patients needed expensive re-administrations, meaning Shield’s drug is a cheaper alternative.

“We believe this will have positive implications for health economic outcomes, pricing strategies and partnering opportunities,” analysts at Edison Group added.

“The next key inflection point is a US partnering deal; we expect Accrufer launch later this year once a partner has been found.”

Quick facts: Shield Therapeutics PLC

Price: 143 GBX

LSE:STX
Market: LSE
Market Cap: £167.58 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Shield Therapeutics makes a profit and is 'cash positive' during first-half...

Shield Therapeutics PLC's (LON:STX), Tim Watts talks to Proactive London about their latest interim results for the six months ended June 30, 2020 which resulted in a profit. Watts looks back to the $11.4m deal signed in January with China's ASK Pharm and the progress made in agreeing the...

4 days, 2 hours ago

2 min read